TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01524965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate mobilisation after locking-plate osteosynthesis
Description: Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard mobilisation after locking plate osteosynthesis
Description: Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis with a locking plate (Philos)
Description: Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with a locking plate (Philos)
Description: Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
Study: NCT04609358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: When patients' hemodynamics was stable, start 1-2ml/kg/hr post-op 6-12 hours and increased 1-2ml/kg/hr each day if tolerating to reach the target energy supply When patients' hemodynamics wasn't stable, start post-op 6-12 hours 0.5-1ml/kg/hr and increased 0.5-1ml/kg/hr each day if tolerating to reach the target energy supply.
Study: NCT01842165

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous injection of 177Lu-octreotate
Description: Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
Study: NCT01967017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01229072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodic
Description: Heparin sodic 150UI/kg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin liquemine
Description: Heparin sodic 150UI/kg
Study: NCT05081349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine
Description: Combination therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide 500 Mg Oral Capsule
Description: Single agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine, 250 Mg Oral Capsule
Description: single agent
Study: NCT01477463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4,000 IU oral vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo and vitamin D
Study: NCT04384445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zofin
Description: Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
Study: NCT02906215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination Intervention
Description: cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
Study: NCT01235364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The Foley catheter was placed with the digital method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The Foley catheter was placed with a speculum
Study: NCT00825058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amibegron (SR58611A)
Description: oral administration 2 X 350mg/day at 12 hours intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration 12 hours intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: oral 20 mg/day
Study: NCT03497546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
Study: NCT01215110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Study: NCT02241356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bifocals
Description: bifocal glasses with an addition of 2.5 Dioptres

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single vision glasses
Description: single vision glasses
Study: NCT01697371

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Study: NCT03561844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy
Description: Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
Study: NCT01215110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275 mg
Study: NCT02502604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
Study: NCT06016595

Intervention type: DIAGNOSTIC_TEST
Intervention: Chronic prostatitis/chronic pelvic pain syndrome
Description: Chronic prostatitis/chronic pelvic pain syndrome UPOINT
Study: NCT02315794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPI®ART
Description: implant prothetic restoration using a yttrium oxide stabilized zirconia abutment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPI®EASY
Description: implant prosthetic restoration using a commercially pure titanium grade 4 abutment
Study: NCT02774863

Intervention type: OTHER
Intervention: Home passages
Description: Three home passages between the 2nd and 3rd months of follow up.
Study: NCT03546166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picato 0.05% Topical Gel
Description: apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
Study: NCT05571007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True acupressure
Description: Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy.
Study: NCT01640418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Border Sacrum dressings
Description: Mepilex® Border Sacrum dressings
Study: NCT02970006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurovisual stimulation
Description: a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
Study: NCT01626118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: capsules, 40 mg, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: capsules, 40 mg, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: capsules, 20 mg, TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study: NCT01173549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Placebo Placebo/Canagliflozin
Description: Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
Study: NCT04527874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VITAL model
Description: The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening.
Study: NCT02638753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: Patients will be educated about pain neurophysiology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education combined with hypnosis
Description: Patients will be educated about pain neurophysiology combined with hypnosis.
Study: NCT05370560

Intervention type: OTHER
Intervention: Plasma transthyretin concentration
Description: Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.

Intervention type: OTHER
Intervention: Plasma transthyretin concentration
Description: Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.

Intervention type: OTHER
Intervention: Plasma transthyretin concentration
Description: Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
Study: NCT02425813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: Given IA and IV
Study: NCT02291302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: air purifier
Description: air purifiers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air purifier
Description: air purifiers

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention (control)
Description: no integrated pest management and sham air purifier
Study: NCT04660292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization
Description: Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical therapy
Description: BASELINE TREATMENT INCLUDES TENS and Hot PACKS
Study: NCT03848208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet
Study: NCT02018276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
Study: NCT01807676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ET View Double Lumen Tube
Study: NCT03848208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet
Study: NCT04174079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
Study: NCT02760654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive Self Management Program for Effects of Cancer Treatment
Study: NCT00786864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise programme
Description: Specific low back pain exercise programme for children
Study: NCT03115099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3325656
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3325656
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3325656
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally
Study: NCT04515992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Body-weight Circuit Training (HIBC)
Description: HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
Study: NCT04501744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 of M701
Description: Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
Study: NCT04501744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 of M701
Description: Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 of M701
Description: Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4 of M701
Description: Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5 of M701
Description: Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6 of M701
Description: Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7 of M701
Description: Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
Study: NCT01308684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441 + bevacizumab [Avastin]
Description: Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
Study: NCT00447837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPRC-AB01
Description: 90 mg/3 mL BID, 180 mg/3 mL bid, placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPRC-AB01
Description: 90 mg/3 mL BID, 180 mg/3 mL bid, placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPRC-AB01
Description: 90 mg/3 mL BID, 180 mg/3 mL bid, placebo
Study: NCT02198417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Treatment with metformin ER for 12 weeks
Study: NCT02261805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study: NCT00981552

Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT planning

Intervention type: RADIATION
Group type: OTHER
Intervention: 4-Field Radiation Planning
Study: NCT03827200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
Study: NCT01792557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystallized phenol
Description: Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limberg Flap
Description: Limberg Flap surgery for pilonidal disease treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Limberg Flap
Description: Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Karydakis Flap
Description: Karydakis Flap surgery for pilonidal disease treatment
Study: NCT00846222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
Study: NCT04425980

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Constraint-Induced Movement Therapy
Description: intensive use of more affected arm in structured setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy
Description: intensive use of more affected arm in structured setting